Mounjar和Zepbound销量飙升,礼来Q3业绩超预期,并上调全年业绩指引

华尔街见闻
Yesterday

得益于减重药Zepbound和糖尿病治疗药物Mounjaro持续强劲的市场需求,礼来第三季度业绩全面超越市场预期并上调全年指引。 礼来周四公布的财报显示,第三季度每股收益7.02美元,超出分析师预期的5.69美元;营收达176亿美元,高于市场预期的160.1亿美元,公司股价在周四盘前交易中上涨5%。 其中,美国销售额飙升45%,达到113亿美元。礼来表示,这主要得益于其产品销量增长60%,尤其是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10